Shares resilient after U.S. tech sell-off, vaccine trial delay
Reuters
Published Sep 08, 2020 22:07
Updated Sep 09, 2020 07:43
By Tom Wilson
LONDON (Reuters) - Shares on Wednesday shrugged off heavy losses for U.S. tech stocks and a major drugmaker delaying testing of a coronavirus vaccine, as investors kept faith in an economic recovery from the coronavirus pandemic.
The broad Euro STOXX 600 (STOXX) gained 0.5%, steadying after a hefty decline a day earlier, sparked by a rout of a U.S. tech sector that has been a key driver of the stunning recovery for global stocks from coronavirus-induced lows.
Wall Street futures (ESc1) (NQc1) were pointing to a bounce for the tech-heavy Nasdaq and the S&P 500, up 1.8% and 0.7% respectively.
London shares (FTSE) gained 0.7%, helped by a pound buffeted by worries about a no-deal Brexit that could hit Britain's economy. Indexes in Frankfurt (GDAXI) and Paris (FCHI) also gained.
Utilities (SX6P), telecoms (SXKP) and healthcare (SXDP) all rose by between 0.6%-2%.
AstraZeneca (L:AZN) shares fell 1.4% after global trials of its experimental COVID-19 vaccine were paused due to an unexplained illness in a study participant. It clawed back heavier losses incurred in premarket trading.
The news had earlier unnerved investors in Asia hoping that the quick introduction of a vaccine would accelerate the recovery for global economies ravaged by the pandemic.
MSCI's broadest index of Asia-Pacific shares outside Japan (MIAPJ0000PUS) slid 1%, with indexes in Australia (AXJO), China (CSI300) and Japan (N225) all skidding.
The Japanese yen
With Big Tech one of the biggest main winners in the global recovery from the coronavirus, benefiting from stay-at-home spenders, investors were mostly sanguine about the sector's prospects, even after the bruising sell-off.
The Nasdaq has shed $1.5 trillion since its Sept. 2 high.
"This has been a correction that was probably not that surprising, given the move in August in the tech sector," said Salman Baig, an investment manager at Unigestion, adding that the outlook for Big Tech was positive.
"It's exactly those companies that are new economy - they are benefiting because of their model, the industry, the virus."
Those attributes have sparked heavy bets from the likes of SoftBank, which has traded heavily in tech stocks call options.
The bets have unnerved investors worried about its exposure to the sector. SoftBank Group (T:9984) shares lost 3% in Tokyo, extending this week's slump that has wiped $15 billion from its market capitalisation.
The MSCI world equity index (MIWD00000PUS), which tracks shares in nearly 50 countries, was down 0.2%.
Despite renewed appetite for stocks, safe-haven German government bond yields (DE10IT10=RR) fell to their lowest in two-weeks. The fall in tech shares also boosted demand for U.S. Treasuries, even though heavy supply this week is expected to weigh on the bonds.
Get The App
VACCINE "BLOW"
The remarkable rally in global shares from their March lows has been driven in part by expectations that a COVID-19 vaccine would be found, helping to accelerate the economic recovery from the coronavirus pandemic.
Yet AstraZeneca's move dims prospects for an early rollout of its vaccine, described by the World Health Organization as probably the world's leading candidate and the most advanced in terms of development.
Deutsche Bank (DE:DBKGn) strategists called the suspension of the trials "a blow".
Elsewhere, sterling GBP=D3 was stalked by fears that Britain is preparing to undercut its Brexit divorce treaty.
Britain will set out later on Wednesday new details of its blueprint for life outside the European Union, publishing legislation a minister acknowledged would break international law and which could sour trade talks.
Sterling dipped 0.4% to $1.2928, its lowest since the end of July, and also fell the same amount against the euro (EURGBP=D3) to 90.70 pence, its lowest for six weeks. One-month implied volatility also hit its highest level in nearly five months.
(For Reuters Live Markets blog on European and UK stock markets, please click on: [LIVE/]; Reporting by Tom Wilson; Editing by Alexandra Hudson)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.